Drug Trial Radar · NCT05363293
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
May 4, 2022
Primary completion
Apr 14, 2023
Study completion May 15, 2023
Sponsor
- Lead sponsor
- Alzamend Neuro, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001. Up to 72 participants will be randomly assigned to receive study drug (active AL001) or placebo. The study consists of a 4-week screening period, a 14-day treatment period, and a 42-day follow-up period.
Conditions
- Alzheimer's Disease
- Healthy Non-elderly and Elderly Adults
Interventions
AL001Drug
a crystal engineered lithium-salicylate-proline lithium delivery product
PlaceboOther
matching placebo formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings.Time frame: 42 days with a 14-day treatment period
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
CenExel iResearch, LLC
Decatur, Georgia
Altasciences
Mount Royal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.